These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 31721467)
1. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial. Yamakage H; Tanaka M; Inoue T; Odori S; Kusakabe T; Satoh-Asahara N J Diabetes Investig; 2020 May; 11(3):653-661. PubMed ID: 31721467 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850 [TBL] [Abstract][Full Text] [Related]
3. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period. Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963 [TBL] [Abstract][Full Text] [Related]
6. Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients. Kosugi R; Nakatani E; Okamoto K; Aoshima S; Arai H; Inoue T Endocr J; 2019 Aug; 66(8):677-682. PubMed ID: 31130574 [TBL] [Abstract][Full Text] [Related]
7. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600 [TBL] [Abstract][Full Text] [Related]
9. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial. Kato K; Suzuki K; Aoki C; Sagara M; Niitani T; Wakamatsu S; Yanagi K; Aso Y Expert Opin Pharmacother; 2017 Jun; 18(8):743-751. PubMed ID: 28426260 [TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S; Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013 [TBL] [Abstract][Full Text] [Related]
11. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298 [TBL] [Abstract][Full Text] [Related]
12. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195 [TBL] [Abstract][Full Text] [Related]
13. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study. Shin Y; Choi H; Lim S Diabetes Res Clin Pract; 2021 May; 175():108843. PubMed ID: 33933498 [TBL] [Abstract][Full Text] [Related]
14. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931 [TBL] [Abstract][Full Text] [Related]
15. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Phrommintikul A; Wongcharoen W; Kumfu S; Jaiwongkam T; Gunaparn S; Chattipakorn S; Chattipakorn N Br J Clin Pharmacol; 2019 Jun; 85(6):1337-1347. PubMed ID: 30767253 [TBL] [Abstract][Full Text] [Related]
17. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853 [TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin. Watanabe Y; Suzuki D; Kuribayashi N; Uchida D; Kato M; Ohashi H; Nagayama D; Yamaguchi T; Ohira M; Saiki A; Tatsuno I Sci Rep; 2021 May; 11(1):11350. PubMed ID: 34059720 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Kaku K; Kiyosue A; Inoue S; Ueda N; Tokudome T; Yang J; Langkilde AM Diabetes Obes Metab; 2014 Nov; 16(11):1102-10. PubMed ID: 24909293 [TBL] [Abstract][Full Text] [Related]
20. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]